Elsevier

Hepatology

Volume 22, Issue 5, November 1995, Pages 1440-1446
Hepatology

Other clinical study
Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody—negative primary biliary cirrhosis

https://doi.org/10.1016/0270-9139(95)90150-7Get rights and content

Abstract

The presence of antimitochondrial antibodies (AMA) is a major criterion for the diagnosis of primary biliary cirrhosis (PBC). Although it is not clear that AMA are involved in the pathogenesis of the disease, the study of these autoantibodies has enabled much information to be accumulated about the specificity of this response. The autoantigens have been identified as components of a functionally related enzyme family, the 2-oxo-acid-dehydrogenase complex. Within this complex, pyruvate dehydrogenase E2 subunit (PDC-E2) has been determined to be the immunodominant autoantigen. Using a panel of mouse monoclonal antibodies and human combinatorial autoantibodies, it has been demonstrated that patients with PBC, but not controls, have an abnormal expression of either PDC-E2 or a cross-reacting molecule in the apical region of biliary epithelium. Others have shown a similar reaction using rabbit sera directed to PDC-E2. Our previous studies have concentrated on AMA-positive patients. In this study, the presence of PDC-E2, class II, immunoglobulin (Ig) A, and B7/BB1 in the bile duct epithelial cells of AMA-positive as well as AMA-negative patients is addressed. Most patients with AMA-negative PBC (seven of nine) react in a fashion similar to AMA-positive patients with intense staining of the apical region of the bile duct epithelial cells for “PDC-E2,” increased IgA expression, and little major histocompatibility complex (MHC) class II staining in the early-stage patients. Interestingly, the two AMA-negative patients that did not express PDC-E2 on the apical side of their biliary epithelium had anticentromere antibodies and Sjögren's syndrome. Based on these data, it can be concluded that the disease process for both AMA-positive and AMA-negative patients with PBC has a similar pathogenic mechanism, which is likely to involve the abnormal expression of PDC-E2 or a molecular mimic of PDC-E2, and does not require MHC class II expression.

References (32)

  • CD Surh et al.

    Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope(s) on protein X and dihydrolipoamide acetyl transferase of pyruvate dehydrogenase complex

    Hepatology

    (1989)
  • DR Fregeau et al.

    Primary biliary cirrhosis: inhibition of pyruvate dehydrogenase complex activity by autoantibodies specific for E1-alpha, a nonlipoic acid containing mitochondrial enzyme

    J Immunol

    (1990)
  • J Van de Water et al.

    Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis

    N Engl J Med

    (1989)
  • PS Leung et al.

    Use of designer recombinant mitochondrial antigens in the diagnosis of primary biliary cirrhosis

    Hepatology

    (1992)
  • N Kitami et al.

    Immunoreactivity to M2 proteins in antimitochondrial auto-antibodies are characteristically present in the serum of patients with primary biliary cirrhosis (PBC)

    J Gastroenterol Hepatol

    (1994)
  • P Michieletti et al.

    Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis

    Gut

    (1994)
  • Cited by (65)

    • Bile Duct Diseases

      2023, MacSween's Pathology of the Liver, Eighth Edition
    • Autoantibodies in Primary Biliary Cholangitis

      2022, Clinics in Liver Disease
      Citation Excerpt :

      It is thought that AMA-negative PBC is a similar disease process to AMA-positive PBC involving abnormal expression of PDC-E2 and/or molecular mimicry of PDC-E2. Tsuneyama and colleagues demonstrated that sera from AMA-negative patients react similarly to sera from AMA-positive patients, with intense staining of the apical region of the bile duct epithelial cells for PDC-E2, suggesting similar disease processes.39 It has been previously proposed that a worse prognosis exists for patients diagnosed with AMA-negative PBC compared with AMA-positive PBC, with reduced transplant-free survival40 and worse bile duct damage around portal areas on histopathology with increased levels of B-cell infiltrates in early phases of bile duct damage.41

    • Bile Duct Diseases

      2018, MacSween's Pathology of the Liver
    • The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis

      2016, Clinics and Research in Hepatology and Gastroenterology
    View all citing articles on Scopus

    Supported by National Institutes of Health, grant no. DK39588, Bethesda, MD.

    View full text